Status:

COMPLETED

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a curre...

Detailed Description

This is a Phase lla open-label (all people involved know the identity of the treatment), randomized (study drug assigned by chance), controlled (the patients of the control group continue the failing ...

Eligibility Criteria

Inclusion

  • Patient has a documented HIV-1 infection with a viral load at screening visit above 2,000 HIV copies/ml
  • Currently treated with a failing antiretroviral regimen consisting of NRTIs together with one or more PI(s)
  • Has a resistance against at least 2 of the currently used PIs
  • Patient agrees not to change the current therapy until end of run-in and agrees not to change NRTIs until the end of treatment period
  • No current AIDS defining illnesses

Exclusion

  • NNRTI (non-nucleoside reverse transcriptase inhibitor) containing regimen, two weeks prior to screening
  • Suspicion of alcohol abuse or drug abuse, leading to non-compliance
  • History of significant drug allergy induced by PIs
  • CD4 count \< 50
  • Life expectancy of less than 6 months
  • Pregnant or breast feeding females
  • Females of childbearing potential without use of a highly effective birth control method or not willing to continue practicing this birth control method for at least 14 days after the end of the treatment
  • Received an investigational drug within 30 days prior to the trial drug administration
  • Patients with clinically significant laboratory abnormalities.

Key Trial Info

Start Date :

August 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2003

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT00964327

Start Date

August 1 2001

End Date

October 1 2003

Last Update

May 19 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.